Published in J Biol Chem on September 08, 2000
Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol (2010) 1.81
Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell (2003) 1.78
The type I BMP receptor BmprIB is essential for female reproductive function. Proc Natl Acad Sci U S A (2001) 1.28
Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A (2005) 1.14
Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Mullerian hormone-induced Mullerian duct regression in the mouse. Biol Reprod (2008) 1.05
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A (2002) 0.99
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci U S A (2004) 0.99
Injection of amniotic fluid stem cells delays progression of renal fibrosis. J Am Soc Nephrol (2012) 0.98
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A (2005) 0.98
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol (2010) 0.95
AMH induces mesonephric cell migration in XX gonads. Mol Cell Endocrinol (2003) 0.93
The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell (2009) 0.92
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology (2007) 0.92
Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours. Int J Androl (2011) 0.91
Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol (2013) 0.91
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol (2010) 0.90
A single base pair mutation encoding a premature stop codon in the MIS type II receptor is responsible for canine persistent Müllerian duct syndrome. J Androl (2008) 0.89
Smad signalling in the ovary. Reprod Biol Endocrinol (2006) 0.88
Regulation of gonadotropin gene expression by Mullerian inhibiting substance. Proc Natl Acad Sci U S A (2003) 0.83
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J (2004) 0.82
Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation. Endocrinology (2012) 0.79
Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors. Obstet Gynecol Sci (2014) 0.79
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. Protein Expr Purif (2009) 0.79
Anti-Müllerian hormone recruits BMPR-IA in immature granulosa cells. PLoS One (2013) 0.78
The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling. Carcinogenesis (2012) 0.78
The TGF-β Family in the Reproductive Tract. Cold Spring Harb Perspect Biol (2017) 0.76
Partial Müllerian Duct Retention in Smad4 Conditional Mutant Male Mice. Int J Biol Sci (2016) 0.75
Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression. Dev Biol (2013) 0.75
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52
Controlling TGF-beta signaling. Genes Dev (2000) 8.13
Climate change. Increasing shrub abundance in the Arctic. Nature (2001) 7.59
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 5.12
Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell (1999) 3.47
Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature (1999) 3.16
The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell (2001) 2.87
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst (1998) 2.39
Electrophoretic resolution of three major insulin receptor structures with unique subunit stoichiometries. Proc Natl Acad Sci U S A (1980) 2.15
Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J (1997) 2.06
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res (1995) 1.95
Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev (1996) 1.75
Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science (2000) 1.66
The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol (2000) 1.55
The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J (1998) 1.54
Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol (1994) 1.46
A unique proteolytic cleavage site on the beta subunit of the insulin receptor. J Biol Chem (1981) 1.46
Affinity labeling of a transforming growth factor receptor that does not interact with epidermal growth factor. Proc Natl Acad Sci U S A (1982) 1.44
Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway. J Biol Chem (2000) 1.35
Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol (1993) 1.29
Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Nat Genet (1995) 1.27
Identification of a nerve growth factor receptor protein in sympathetic ganglia membranes by affinity labeling. J Biol Chem (1981) 1.23
Molecular mechanisms of hormone-mediated Müllerian duct regression: involvement of beta-catenin. Development (2000) 1.23
Anti-müllerian hormone: the Jost factor. Recent Prog Horm Res (1993) 1.21
Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol (2001) 1.19
Persistence of Müllerian derivatives in males. Am J Med Genet (1999) 1.18
Production of anti-Müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology (1984) 1.16
Contributions of pathway and neuron to preferential motor reinnervation. J Neurosci (1998) 1.15
Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab (1999) 1.15
Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem (2000) 1.14
Affinity labeling of multiplication stimulating activity receptors in membranes from rat and human tissues. J Biol Chem (1981) 1.14
Source of the anti-Müllerian hormone synthesized by the fetal testis: Müllerian-inhibiting activity of fetal bovine Sertoli cells in tissue culture. Pediatr Res (1974) 1.07
Effects of artificial liver support system on patients with acute or chronic liver failure. Transplant Proc (2005) 1.07
BF-1 interferes with transforming growth factor beta signaling by associating with Smad partners. Mol Cell Biol (2000) 1.06
Early expression of AMH in chicken embryonic gonads precedes testicular SOX9 expression. Dev Dyn (1998) 1.06
Insulin action rapidly modulates the apparent affinity of the insulin-like growth factor II receptor. J Biol Chem (1983) 1.06
Purification of testicular anti-Müllerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol Cell Endocrinol (1984) 1.05
Receptors for anti-müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc Natl Acad Sci U S A (1998) 1.04
Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol (1996) 1.02
Anti-müllerian hormone in early human development. Early Hum Dev (1993) 1.01
Hormonal and cellular regulation of Sertoli cell anti-Müllerian hormone production in the postnatal mouse. J Clin Invest (1997) 1.00
Components of the anti-Müllerian hormone signaling pathway in gonads. Mol Cell Endocrinol (2003) 0.99
Anti-Müllerian hormone produces endocrine sex reversal of fetal ovaries. Proc Natl Acad Sci U S A (1989) 0.99
Anti-müllerian hormone and testosterone serum levels are inversely during normal and precocious pubertal development. J Clin Endocrinol Metab (1993) 0.99
When true recognition suppresses false recognition: evidence from amnesic patients. J Cogn Neurosci (1998) 0.98
Preservation of gonadal function in true hermaphroditism. J Pediatr Surg (1984) 0.97
The role of anti-Müllerian hormone in gonadal development. Mol Cell Endocrinol (1998) 0.96
The anti-Müllerian hormone. Birth Defects Orig Artic Ser (1977) 0.96
The yeast KEX-2-processing endoprotease is active in the Golgi apparatus of transfected NIH 3T3 fibroblasts. Mol Endocrinol (1990) 0.96
The antimüllerian hormone. Recent Prog Horm Res (1976) 0.95
A 27 base-pair deletion of the anti-müllerian type II receptor gene is the most common cause of the persistent müllerian duct syndrome. Hum Mol Genet (1996) 0.94
Radiological findings in three cases of persistent müllerian duct syndrome. Pediatr Radiol (1993) 0.94
Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice. Endocrinology (2001) 0.93
A quantitative and interspecific test for biological activity of anti-müllerian hormone: the fetal ovary aromatase assay. Development (1992) 0.93
Affinity labeling of a nerve growth factor receptor component on rat pheochromocytoma (PC12) cells. Biochim Biophys Acta (1982) 0.93
Anti-müllerian hormone in children with androgen insensitivity. J Clin Endocrinol Metab (1994) 0.93
Mapping of the gene for anti-müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet (1987) 0.93
Ontogeny of reproductive abnormalities induced by deregulation of anti-müllerian hormone expression in transgenic mice. Biol Reprod (1995) 0.92
Subunit structure and dynamics of the insulin receptor. Fed Proc (1982) 0.92
Localization of anti-Müllerian hormone in the rough endoplasmic reticulum of the developing bovine sertoli cell using immunocytochemistry with a monoclonal antibody. Endocrinology (1982) 0.92
Testicular degeneration in three patients with the persistent müllerian duct syndrome. Eur J Pediatr (1995) 0.91
Testicular dysgenesis does not affect expression of anti-müllerian hormone by Sertoli cells in premeiotic seminiferous tubules. Am J Pathol (1996) 0.91
High specificity of Müllerian-inhibiting substance signaling in vivo. Endocrinology (1999) 0.91
The actions of insulin-like growth factors I and II on cultured Sertoli cells. Endocrinology (1984) 0.91
Cloning and expression of cDNA for anti-müllerian hormone. Proc Natl Acad Sci U S A (1986) 0.90
Embryonic testicular regression syndrome: variable phenotypic expression in siblings. J Pediatr (1980) 0.90
Use of monoclonal antibody techniques to study the ontogeny of bovine anti-Müllerian hormone. J Reprod Fertil (1983) 0.89
Anti-Müllerian hormone Bruxelles: a nonsense mutation associated with the persistent Müllerian duct syndrome. Proc Natl Acad Sci U S A (1991) 0.89
Immunocytochemical detection of anti-müllerian hormone in Sertoli cells of various mammalian species including human. J Histochem Cytochem (1987) 0.89
Luteinizing hormone-dependent activity and luteinizing hormone-independent differentiation of rat fetal Leydig cells. Mol Cell Endocrinol (2001) 0.89
Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab (1999) 0.89
Cloning and expression of the chick anti-Müllerian hormone gene. J Biol Chem (1996) 0.89
Evolution of the Müllerian-inhibiting activity of the human testis. Effect of fetal, peri-natal and post-natal human testicular tissue on the Müllerian duct of the fetal rat in organ culture. Biol Neonate (1972) 0.89
Purified bovine AMH induces a characteristic freemartin effect in fetal rat prospective ovaries exposed to it in vitro. Development (1987) 0.88
Effects of pathway and neuronal aging on the specificity of motor axon regeneration. Exp Neurol (2001) 0.87
Executive dysfunction in frontotemporal dementia is related to abnormalities in frontal white matter tracts. J Neurol (2011) 0.87
Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Mol Endocrinol (1993) 0.87
Disorders of gonadal differentiation and congenital adrenal hyperplasia. Endocrinol Metab Clin North Am (1988) 0.86
Expression of the gene for anti-Müllerian hormone. J Reprod Fertil (1990) 0.86
Immunocytochemical study of anti-Müllerian hormone in sheep ovarian follicles during fetal and post-natal development. J Reprod Fertil (1987) 0.86
Biochemical analysis of bovine testicular anti-Müllerian hormone. FEBS Lett (1986) 0.86
Anti-Müllerian hormone. Physiol Rev (1986) 0.86
Regulation of testicular anti-M ullerian hormone secretion. Eur J Endocrinol (1996) 0.85
Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families. Hum Mol Genet (1994) 0.85
Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev (2002) 0.85
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol (2002) 0.85
Permeability of membranes to the Müllerian-inhibiting substance synthesized by the human fetal testis in vitro: a clue to its biochemical nature. J Clin Endocrinol Metab (1972) 0.85
Secretion of anti-Müllerian hormone by immature bovine Sertoli cells in primary culture, studied by a competition-type radioimmunoassay: lack of modulation by either FSH or testosterone. Mol Cell Endocrinol (1985) 0.84
Biosynthesis of labelled anti-müllerian hormone by fetal testes: evidence for the glycoprotein nature of the hormone and for its disulfide-bonded structure. Mol Cell Endocrinol (1978) 0.84
Investigation of a possible role of the amino-terminal pro-region of proopiomelanocortin in its processing and targeting to secretory granules. Mol Cell Endocrinol (1991) 0.84
Intracellular proteolytic processing of proopiomelanocortin in heterologous COS-1 cells by the yeast KEX2 endoprotease. Biochem Cell Biol (1990) 0.84